Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
India · Delayed Price · Currency is INR 302.00
+5.05 (1.70%)
Feb 17, 2026, 3:30 PM IST
NSE:ADVENZYMES Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 7,096 | 6,369 | 6,239 | 5,406 | 5,294 | 5,018 |
| 7,096 | 6,369 | 6,239 | 5,406 | 5,294 | 5,018 | |
Revenue Growth (YoY) | 13.07% | 2.09% | 15.39% | 2.13% | 5.49% | 13.03% |
Cost of Revenue | 1,955 | 1,653 | 1,576 | 1,420 | 1,181 | 1,056 |
Gross Profit | 5,140 | 4,716 | 4,663 | 3,987 | 4,113 | 3,962 |
Selling, General & Admin | 1,658 | 1,501 | 1,355 | 1,217 | 1,099 | 898.46 |
Other Operating Expenses | 1,367 | 1,269 | 1,260 | 1,163 | 999.22 | 740.03 |
Operating Expenses | 3,424 | 3,136 | 2,967 | 2,730 | 2,448 | 1,926 |
Operating Income | 1,716 | 1,580 | 1,695 | 1,257 | 1,665 | 2,036 |
Interest Expense | -28.66 | -35.57 | -29.28 | -24.21 | -17.96 | -16.09 |
Interest & Investment Income | 198.06 | 198.06 | 133.26 | 94.83 | 4.04 | 5.85 |
Currency Exchange Gain (Loss) | 9.75 | 9.75 | 5.49 | 13.02 | 2.46 | -1.62 |
Other Non Operating Income (Expenses) | 92.01 | 58.93 | 93.38 | 36.78 | 35.43 | 26.94 |
EBT Excluding Unusual Items | 1,987 | 1,811 | 1,898 | 1,377 | 1,689 | 2,051 |
Gain (Loss) on Sale of Investments | 58 | 58 | 86.13 | -27.24 | - | - |
Gain (Loss) on Sale of Assets | 2.29 | 2.29 | -3.05 | -7.51 | 11.5 | 7.25 |
Asset Writedown | - | - | - | -6.87 | - | - |
Legal Settlements | - | - | -151.32 | - | - | - |
Other Unusual Items | 114.44 | 1.98 | 48.2 | 68.27 | 10.26 | 42.66 |
Pretax Income | 2,162 | 1,874 | 1,878 | 1,404 | 1,711 | 2,101 |
Income Tax Expense | 611.09 | 533.9 | 508.7 | 365.22 | 472.59 | 588.45 |
Earnings From Continuing Operations | 1,551 | 1,340 | 1,370 | 1,039 | 1,238 | 1,513 |
Minority Interest in Earnings | -28.46 | -28.59 | -36.46 | 17.73 | -42.17 | -53.56 |
Net Income | 1,522 | 1,311 | 1,333 | 1,056 | 1,196 | 1,459 |
Net Income to Common | 1,522 | 1,311 | 1,333 | 1,056 | 1,196 | 1,459 |
Net Income Growth | 14.51% | -1.64% | 26.19% | -11.66% | -18.06% | 12.87% |
Shares Outstanding (Basic) | 112 | 112 | 112 | 112 | 112 | 112 |
Shares Outstanding (Diluted) | 112 | 112 | 112 | 112 | 112 | 112 |
Shares Change (YoY) | -0.01% | 0.10% | 0.06% | -0.05% | - | 0.06% |
EPS (Basic) | 13.60 | 11.72 | 11.92 | 9.45 | 10.70 | 13.06 |
EPS (Diluted) | 13.59 | 11.71 | 11.92 | 9.45 | 10.68 | 13.04 |
EPS Growth | 14.49% | -1.76% | 26.17% | -11.54% | -18.10% | 12.80% |
Free Cash Flow | - | 1,087 | 990.56 | 1,023 | 941.75 | 1,435 |
Free Cash Flow Per Share | - | 9.71 | 8.85 | 9.14 | 8.42 | 12.83 |
Dividend Per Share | 5.200 | 5.200 | 5.100 | 1.000 | 1.000 | 0.900 |
Dividend Growth | 1.96% | 1.96% | 410.00% | - | 11.11% | 50.00% |
Gross Margin | 72.44% | 74.05% | 74.74% | 73.74% | 77.69% | 78.95% |
Operating Margin | 24.18% | 24.81% | 27.18% | 23.25% | 31.45% | 40.58% |
Profit Margin | 21.45% | 20.59% | 21.37% | 19.54% | 22.59% | 29.08% |
Free Cash Flow Margin | - | 17.07% | 15.88% | 18.91% | 17.79% | 28.60% |
EBITDA | 1,980 | 1,839 | 1,948 | 1,507 | 1,918 | 2,228 |
EBITDA Margin | 27.91% | 28.88% | 31.22% | 27.87% | 36.23% | 44.41% |
D&A For EBITDA | 264.42 | 259.24 | 252.33 | 249.92 | 252.95 | 192.1 |
EBIT | 1,716 | 1,580 | 1,695 | 1,257 | 1,665 | 2,036 |
EBIT Margin | 24.18% | 24.81% | 27.18% | 23.25% | 31.45% | 40.58% |
Effective Tax Rate | 28.27% | 28.49% | 27.08% | 26.02% | 27.63% | 28.00% |
Revenue as Reported | 7,459 | 6,700 | 6,605 | 5,661 | 5,358 | 5,107 |
Advertising Expenses | - | 75.56 | 62.19 | 63.96 | 55.92 | 26.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.